Personalis Inc
NASDAQ:PSNL

Watchlist Manager
Personalis Inc Logo
Personalis Inc
NASDAQ:PSNL
Watchlist
Price: 6.09 USD 2.35%
Market Cap: 430.3m USD
Have any thoughts about
Personalis Inc?
Write Note

Operating Margin
Personalis Inc

-80.1%
Current
-124%
Average
3.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-80.1%
=
Operating Profit
-70.1m
/
Revenue
87.5m

Operating Margin Across Competitors

Country US
Market Cap 430.2m USD
Operating Margin
-80%
Country US
Market Cap 1.2T USD
Operating Margin
14%
Country US
Market Cap 202.3B USD
Operating Margin
17%
Country US
Market Cap 166.6B USD
Operating Margin
21%
Country KR
Market Cap 66.8T KRW
Operating Margin
31%
Country CH
Market Cap 38.4B CHF
Operating Margin
13%
Country US
Market Cap 38.8B USD
Operating Margin
24%
Country US
Market Cap 36.3B USD
Operating Margin
14%
Country US
Market Cap 27B USD
Operating Margin
28%
Country US
Market Cap 24.1B USD
Operating Margin
20%
Country CN
Market Cap 162B CNY
Operating Margin
27%
No Stocks Found

Personalis Inc
Glance View

Market Cap
430.2m USD
Industry
Life Sciences Tools & Services

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company is headquartered in Menlo Park, California and currently employs 325 full-time employees. The company went IPO on 2019-06-20. The firm is focused on the development of therapies by providing molecular data about each patient's cancer and immune response. The company provides sequencing and data analysis services to support the development of cancer therapies. Its NeXT Platform, which provides its biopharmaceutical customers with information on over 20,000 human genes, together with the immune system, in contrast to many cancer panels that cover over 50 to 500 genes. Its NeXT Platform is designed to provide analysis of both a tumor and its immune microenvironment from a single limited tissue sample. Its platform covers the deoxyribonucleic acid sequence of all of the approximately 20,000 human genes. The company also reports on transcriptome of a tumor, which encompasses ribonucleic acid expression across human genes, allowing it to determine which of the genomic mutations might actually be driving tumor progression.

PSNL Intrinsic Value
1.97 USD
Overvaluation 68%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-80.1%
=
Operating Profit
-70.1m
/
Revenue
87.5m
What is the Operating Margin of Personalis Inc?

Based on Personalis Inc's most recent financial statements, the company has Operating Margin of -80.1%.